Scarica l'app Stockscreener
755.02
1.83%
13.57
Pre-mercato:
755.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$741.45
Aprire:
$732.92
Volume 24 ore:
692.59K
Relative Volume:
0.71
Capitalizzazione di mercato:
$79.35B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
18.16
EPS:
41.5659
Flusso di cassa netto:
$3.88B
1 W Prestazione:
-1.00%
1M Prestazione:
-2.74%
6M Prestazione:
+35.10%
1 anno Prestazione:
+12.19%
Intervallo 1D:
$731.51
$763.56
Intervallo di 1 settimana:
$731.51
$776.25
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
755.02 | 77.93B | 14.34B | 4.50B | 3.88B | 41.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.01 | 119.22B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
835.68 | 52.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.11 | 44.66B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.00 | 37.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron (REGN)? - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Promising 15% Upside as Analysts Rally Behind Biotech Giant - DirectorsTalk Interviews
Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? - Stocktwits
Where Regeneron Pharmaceuticals Stands With Analysts - Benzinga
JP Morgan Raises Price Target for REGN to $950 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $950.00 at JPMorgan Chase & Co. - MarketBeat
Regeneron Pharmaceuticals (REGN) Gets Analyst Boost with Revised Price Target | REGN Stock News - GuruFocus
Oppenheimer Reaffirms Outperform Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $769.00 at Morgan Stanley - MarketBeat
Analyst Matthew Harrison Maintains Equal-Weight Rating for REGN | REGN Stock News - GuruFocus
Wells Fargo Raises Price Target for Regeneron Pharmaceuticals (R - GuruFocus
REGN: Cantor Fitzgerald Raises Price Target to $800, Maintains O - GuruFocus
Cantor Fitzgerald Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $800.00 - MarketBeat
Truist Financial Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Truist Securities Maintains Buy Rating on REGN, Lowers Price Target | REGN Stock News - GuruFocus
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $916, Maintains Outperform Rating - marketscreener.com
Regeneron (REGN) Boosts Dividend by 6.8%, Expects Strong Growth - GuruFocus
Oppenheimer Raises Price Target on Regeneron Pharmaceuticals to $865 From $750, Keeps Outperform Rating - marketscreener.com
Regeneron to present new EYLEA HD data at Angiogenesis meeting - Investing.com
Regeneron (REGN) Highlights Advances in Ophthalmology with EYLEA HD - GuruFocus
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases - The Manila Times
Eye drug EYLEA HD offers fewer eye injections in fresh trial data - Stock Titan
This Top Non-Tech AI Trade for 2026 Pays a Huge 11.6% Dividend - Investing.com
AE Wealth Management LLC Buys 1,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock slips premarket even after Wall Street lifts targets on strong Q4 — what’s weighing on the stock? - MSN
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Action Alert: Sanofi/Regeneron, Merck, REGENXBIO and More - BioSpace
Regeneron Pipeline Progress And Valuation Gap Put Future Growth In Focus - Yahoo Finance
Regeneron Q4 Growth Highlights Expanding Pipeline And Upcoming FDA Decisions - simplywall.st
National Pension Service Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Aug Catalysts: Is Regeneron Pharmaceuticals Inc part of any ETFJuly 2025 Technicals & Consistent Growth Equity Picks - baoquankhu1.vn
Regeneron (REGN) Draws Higher Target From TD Cowen - Finviz
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines - Finviz
How Regeneron Pharmaceuticals Inc. (REGN) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Regeneron (REGN) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Regeneron: Expect Double-Digit Growth In 2026 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by TD Waterhouse Canada Inc. - MarketBeat
Wall Street Zen Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold - MarketBeat
Regeneron Pharmaceuticals (REGN) Margin Slippage Tests Bullish Earnings Growth Narrative - simplywall.st
10 Most Profitable Healthcare Stocks to Buy - Insider Monkey
Regeneron’s Earnings Call: Growth Engines and Rising Costs - TipRanks
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Raises Dividend to $0.94 Per Share - MarketBeat
Regeneron (REGN) Reports Strong Q4 2025 Revenue Growth - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highl - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target - TipRanks
Key facts: Regeneron gains FDA approval; Q4 revenue rises 3%; trials for weight-loss drug start - TradingView
Regeneron bets added cholesterol benefit will help its obesity drug stand out - WTVB
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):